Meeting
2022 ASCO Annual Meeting
BASECAMP-1: Leveraging human leukocyte antigen (HLA) loss of heterozygosity (LOH) in solid tumors by next-generation sequencing (NGS) to identify patients with relapsed solid tumor for future logic-gated Tmod CAR T-cell therapy.
Authors
Diane M. Simeone
Department of Surgery, New York University Langone Health, New York, NY
Diane M. Simeone , J. Randolph Hecht , Sandip Pravin Patel , Maria Pia Morelli , Kedar Kirtane , Mitesh J. Borad , Marcela Valderrama Maus , John B. Sunwoo , Theodore Welling , Yi Lin , Edward B. Garon , Scott Kopetz , Frederick L. Locke , Kirstin B. Liechty , Ariane Lozac'hmeur , Karl Beutner , Eric Wai-Choi Ng , William Y. Go , David G. Maloney , Julian R. Molina
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Cellular Immmunotherapy
Clinical Trial Registration Number
NCT04981119
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS2676)
DOI
10.1200/JCO.2022.40.16_suppl.TPS2676
Abstract #
TPS2676
Poster Bd #
327a
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Prospective BASECAMP-1 experience in patients with gastrointestinal (GI) cancer: Identifying patients with human leukocyte antigen (HLA) loss of heterozygosity (LOH) for a future therapeutic trial exploiting LOH as a tumor vulnerability.
First Author: J. Randolph Hecht
Poster
2022 ASCO Annual Meeting
First-in-human dose escalation and expansion study of MT-6402, a novel engineered toxin body (ETB) targeting PD-L1, in patients with PD-L1 expressing relapsed/refractory advanced solid tumors: Interim data.
First Author: Eugene R Ahn
Poster
2024 ASCO Annual Meeting
Initial data from a phase 1, first-in-human clinical trial for T-Plex, a multiplexed, enhanced T cell receptor-engineered T cell therapy (TCR-T) for solid tumors.
First Author: Sajeve Samuel Thomas
Poster
2023 ASCO Annual Meeting
Five-year follow-up update of defined-composition CD19 CAR T-cell therapy for relapsed/refractory CLL.
First Author: Emily C. Liang